Page 21 - Noble-Virtual-Healthcare-2024

Cadrenal Therapeutics, Inc.

SELECTED FINANCIAL ITEMS CVKD

(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (4.20) (1.03) (1.14) (1.26) (7.63)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (5.17) (1.00) (1.04) (1.14) (8.36)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 4.48 3.56 9.31 8.52 8.52
Cash & Short Term Investments 4.03 3.23 9.11 8.40 8.40
% of Assets 90% 91% 98% 99% 99%
Current Assets -Total 4.44 3.52 9.28 8.49 8.49
% of Assets 99% 99% 100% 100% 100%
Total Liabilities 0.42 0.38 0.57 0.83 0.83
% of Assets 9% 11% 6% 10% 10%
Current Liabilities - Total 0.40 0.37 0.56 0.83 0.83
% of Assets 9% 11% 6% 10% 10%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 4.07 3.18 8.75 7.69 7.69
% of Assets 91% 89% 94% 90% 90%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (1.41) (0.80) (0.63) (0.69) (3.53)
Net Cash Flow - Investing NA (0.00) (0.00) 0.00 (0.00)
Net Cash Flow - Financing 5.41 0.00 6.51 (0.01) 11.90

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference